Journal: Chinese Journal of Cancer Research
Article Title: A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera ® ) in patients with CD20-positive B-cell non-Hodgkin lymphoma
doi: 10.21147/j.issn.1000-9604.2022.06.08
Figure Lengend Snippet: Changes of peripheral blood CD20-positive B-cell absolute counts. Rituximab refers to MabThera®. pcs, pieces.
Article Snippet: Ripertamab (SCT400), a recombinant human-mouse chimeric anti-CD20 immunoglobulin G1 (IgG1) monoclonal antibody developed by Sinocelltech Ltd, Beijing, China, has the same amino acid sequence of antigen binding sites and variable region to rituximab, except one amino acid difference in position 219 of heavy chain constant region 1 (valine in ripertamab and alanine in rituximab).
Techniques: